Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The combination of docetaxel+epirubicin is highly effective and well tolerated as first line
treatment in patients with metastatic breast cancer (MBC). Capecitabine is an active drug in
women with MBC pretreated with taxane and anthracycline. Docetaxel increases the
intracellular levels of thymidilate phosphorylase and thus is synergistic with capecitabine.
The combination of docetaxel plus capecitabine is highly active and superior to docetaxel
monotherapy in women with MBC pretreated with an anthracycline